The purification and characterization of an acellular pertussis vaccine.
An acellular pertussis vaccine manufactured by Biken was investigated for purity, potency and toxicity. The vaccine was composed of almost equal proportions of pertussis toxin (PT) and filamentous hemagglutinin (FHA). The purity of the vaccine was 97-99%. The protective effects of component vaccines containing various ratios of PT and FHA were tested and it was found that the ratio of 1:1 provided the most effective vaccine.
D000818:Animals; D001886:Bordetella pertussis / Q000032:analysis; D005069:Evaluation Studies as Topic; D006388:Hemagglutinins / Q000302:isolation & purification; D051379:Mice; D037342:Pertussis Toxin; D010567:Pertussis Vaccine / Q000302:isolation & purification* / Q000592:standards; D010566:Virulence Factors, Bordetella / Q000302:isolation & purification
D006388:Hemagglutinins; D010567:Pertussis Vaccine; D010566:Virulence Factors, Bordetella; D037342:Pertussis Toxin